- Home
- ABP vs NCNA Comparison
ABP vs NCNA Comparison
Compare ABP & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABP | NCNA |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 13.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ABP | NCNA |
|---|---|---|
| Price | $1.09 | $2.17 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 69.1K |
| Earning Date | 04-02-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 50.00 | N/A |
| 52 Week Low | $1.12 | $2.07 |
| 52 Week High | $34.65 | $268.00 |
Technical Indicators
Market Signals| Indicator | ABP | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 21.88 | 26.27 |
| Support Level | $1.44 | $2.13 |
| Resistance Level | $2.89 | $2.33 |
| Average True Range (ATR) | 0.38 | 0.18 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 0.01 | 10.34 |
Price Performance
Historical ComparisonAbout ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.